Axitinib 319460-85-0
Developed by Pfizer, Axitinib CAS# 319460-85-0 is a small molecule tyrosine kinase inhibitor. As of December 7, 2011 the Oncologic Drugs Advisory Committee voted to approve Axitinib (Inlyta) as a second-line treatment for patients with Advanced Renal Cell Carcinoma. Phase 2 trials showed promise for patients with Breast Cancer, as Axitinib showed to inhibit tumor growth. Axitinib is an inhibitor for Vascular Endothelial Growth Factor receptors 1,2 and 3, and hypertension is often considered to be a common side effect for these anti VEGF drugs. Reported dosage for trials of Axinitib were five milligrams, given twice daily.
read more [+]| Systematic (IUPAC) name: | N-Methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide |
|---|---|
| Axitinib CAS number: | 319460-85-0 |
| ATC code: | L01XE17 |
| PubChem: | 6450551 |
| DrugBank: | |
| Formula: | C22H18N4O1 |
| Molecular mass: | 386.469 g/mol |
| Axitinib Assay/Purity: | Typically NLT 98% |
